NASDAQ
Immunovant, Inc. (IMVT)
♥ 391 Thanks from members
Immunovant, Inc. (IMVT) exhibits a mixed yet resilient market profile: despite reporting a wider-than-expected Q1 2026 EPS loss driven by intensified clinical R&D spending, the stock retains strong analyst confidence with projected upside, trading near technical resistance levels amid broader biotech sector jitters.